GET DAILY SIGNALSNeumora Therapeutics (NMRA) Rises +19% Over 30 Days After Hitting Oversold Lows
Key Takeaways
- NMRA climbed roughly 19% over the trailing 30 days, from about $0.50 to roughly $0.60, after touching a 52-week low near $0.32 in mid-October.
- The rebound reflects positioning ahead of near-term catalysts, including fourth-quarter clinical data readouts and a scheduled earnings report, as well as a recovery from deeply oversold conditions.
- Over the trailing three months, the stock remains sharply lower, down roughly 55% from about $1.33 in late August.
- Neumora is a clinical-stage neuroscience company whose lead depression candidate, navacaprant, was discontinued in 2026 after Phase 3 trial setbacks, prompting an approximately 35% workforce reduction.
- The company ended the first half of 2026 with about $116.8 million in cash, which management has indicated is expected to fund operations into the third quarter of 2027.
- Because NMRA trades below $1, it faces Nasdaq listing-compliance requirements and must rebuild sustained price support.
- Investors seeking additional context can review Neumora's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see AI-driven trading strategies across the broader market.
Company Background and Pipeline Focus
Neumora Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2019, it focuses on a precision-neuroscience strategy that blends data science with neuroscience research to create brain-penetrant treatments for neuropsychiatric, neurodegenerative, and metabolic conditions.
Its pipeline centers on three primary programs: NMRA-511, a vasopressin 1a receptor antagonist aimed at agitation linked to Alzheimer's disease; NMRA-898, an M4 muscarinic positive allosteric modulator under study for schizophrenia; and NMRA-215, a brain-penetrant NLRP3 inhibitor directed at obesity and related metabolic issues. Earlier-stage efforts also target Parkinson's disease and ALS.
With no approved products or product revenue, the company's valuation hinges on clinical progress and development milestones. I find this binary, catalyst-driven profile keeps the stock highly volatile, which is why I monitor NMRA closely during key periods.
Stock Performance Over the Past 30 Days and Quarter
In the last 30 days, NMRA advanced roughly 19%, moving from about $0.50 early in October to around $0.60. The move was not steady; the shares first fell to a 52-week low near $0.32 on October 14 before rebounding sharply into early November.
Looking back further, the three-month picture is weaker, with the stock down roughly 55% from around $1.33 in late August. This longer decline stems from ongoing repricing after the depression-program challenges and a gradual slide toward historic lows.
Drivers of the Recent 30-Day Move
The rally occurred in distinct phases. Early on, selling continued as investors absorbed the 2026 discontinuation of navacaprant following Phase 3 KOASTAL trial shortfalls. That step came with an approximately 35% workforce cut and sent the shares to their 52-week low near $0.32 on October 14.
Positioning for upcoming catalysts then supported the rebound. Neumora has pointed to several fourth-quarter 2026 data releases, such as results from the NMRA-511 multiple-ascending-dose expansion cohort in Alzheimer's agitation and Phase 1 data for NMRA-898 in schizophrenia, plus plans to move NMRA-215 into the clinic. A third-quarter earnings release was also set for early November.
Technical conditions likely played a role as well. The stock began the period deeply oversold and below $1, with short interest near 10% of the float as of late August and elevated beta, factors that can intensify rebounds in small-cap biotechs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quarterly Performance and Strategic Reset
The three-month decline aligns with a broader repositioning. In August, the company reported second-quarter results, confirmed the shift away from navacaprant, and outlined a pipeline centered on NMRA-511, NMRA-898, and NMRA-215 while naming Joshua Pinto as chief executive officer.
The market has adjusted valuations to reflect the move from a late-stage depression focus to an earlier-stage pipeline with multiple data events ahead. Price targets have been reduced, and shares slipped below $1, raising Nasdaq compliance questions. Positive NMRA-215 toxicology findings in late July offered a brief lift, yet broader caution in small-cap biotech kept pressure on the shares.
Key Items to Watch in the Months Ahead
- NMRA-511 data from the multiple-ascending-dose expansion cohort in Alzheimer's agitation, due in the fourth quarter of 2026, followed by a planned Phase 2 start.
- NMRA-898 Phase 1 results in schizophrenia, expected in the second half of 2026.
- NMRA-215 regulatory steps, including an investigational new drug filing and possible Phase 1 launch.
- Quarterly earnings and any updates on cash runway, with focus on whether the position continues to support operations into the third quarter of 2027.
- Nasdaq listing compliance, given the sub-$1 price, and any financing or consolidation actions that follow.
- Overall biotech sentiment and competitive updates in Alzheimer's agitation, schizophrenia, and obesity areas.
Using AI Tools to Refine Research
In my analysis of volatile names like NMRA, I have found Tickeron's Trending AI Robots page helpful for reviewing systematic strategies. It curates top-performing bots across different timeframes and approaches, offering an extra data-driven perspective on market behavior without replacing core fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NMRA in +55.47% Uptrend, growing for three consecutive days on November 03, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Oscillator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 27 of 31 cases where NMRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on NMRA as a result. In 42 of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 17 of 20 cases over the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NMRA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NMRA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.410) is normal, around the industry mean (3.051). P/E Ratio (-0.464) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement